PT-141 12.5 mg (Bremelanotide)

Biochem PT-141 12.5 mg (Bremelanotide) – Melanocortin Receptor Agonist

Biochem PT-141 12.5 mg, also known as Bremelanotide, is a synthetic cyclic heptapeptide belonging to the melanocortin receptor agonist family. PT-141 has been studied for its effects on central nervous system pathways associated with sexual desire, sexual motivation, and neuroendocrine signaling.

Bremelanotide is derived from the melanocortin peptide family and is structurally related to alpha-melanocyte-stimulating hormone (α-MSH), an endogenous peptide involved in several physiological processes, including pigmentation, appetite regulation, and central nervous system signaling.

Unlike phosphodiesterase type 5 (PDE5) inhibitors, which primarily influence peripheral vascular processes associated with erectile function, PT-141 acts through melanocortin receptors and affects central pathways involved in sexual response.

Bremelanotide interacts with several melanocortin receptor subtypes, including MC1R, MC3R, MC4R, and MC5R. Its effects on sexual behavior are believed to involve central melanocortin signaling, particularly pathways associated with MC4R, although the precise mechanism underlying its clinical effects has not been fully established.

Pharmaceutical bremelanotide has an established medical application for acquired, generalized hypoactive sexual desire disorder (HSDD) in selected premenopausal women. Clinical evidence for other populations and indications is more limited, and results from approved pharmaceutical preparations cannot automatically be applied to products with unverified formulations.

PT-141 is not an anabolic-androgenic steroid, testosterone derivative, or direct sex hormone replacement. Its pharmacological properties are associated with neuropeptide receptor signaling rather than direct androgen receptor activation.

The Biochem PT-141 formulation contains a labeled quantity of 12.5 mg per vial. The precise salt form, excipients, physical presentation, and manufacturing specifications have not been independently verified.

1. Influences Central Melanocortin Signaling

PT-141 activates melanocortin receptors involved in central nervous system signaling. These receptors participate in several physiological processes, including behavioral responses, neuroendocrine regulation, and pathways associated with sexual motivation.

2. Influences Sexual Desire Pathways

Bremelanotide has been clinically studied for its effects on sexual desire in premenopausal women with acquired, generalized hypoactive sexual desire disorder. Controlled clinical trials have demonstrated improvements in certain patient-reported measures of sexual desire, although treatment responses vary between individuals.

3. Interacts With MC4R-Associated Pathways

Melanocortin receptor 4 is expressed in several regions of the central nervous system and participates in neurobehavioral and metabolic regulation. PT-141-associated effects on sexual response are believed to involve melanocortin signaling pathways that include MC4R.

4. Exhibits Distinct Activity From PDE5 Inhibitors

Unlike sildenafil and other PDE5 inhibitors, bremelanotide does not primarily work by inhibiting phosphodiesterase enzymes or directly increasing peripheral nitric oxide-mediated vasodilation. Its activity is associated with melanocortin receptor signaling in the nervous system.

5. Has Been Examined in Male Sexual Function Models

PT-141 has been studied in experimental and early clinical settings involving male sexual response and erectile function. These findings do not establish the same level of clinical effectiveness or an equivalent medical indication as its established use in selected premenopausal women.

6. Influences Neurobehavioral Signaling

Melanocortin receptors participate in pathways associated with motivation, behavioral responses, and physiological regulation. PT-141 has been examined for its effects on these receptor-mediated processes, although its full range of neurobehavioral effects remains incompletely characterized.

7. Exhibits Systemic Melanocortin-Associated Effects

Bremelanotide can produce effects beyond sexual desire pathways, including transient increases in blood pressure, reductions in heart rate, nausea, and changes in pigmentation. These effects are clinically relevant because melanocortin receptors participate in multiple physiological systems.

The biological effects of PT-141 depend on the preparation, route of administration, receptor activity, individual physiological response, and underlying medical condition. Pharmaceutical bremelanotide has demonstrated efficacy for a specific clinical indication, but this does not establish effectiveness for every proposed application.

PT-141 is a synthetic cyclic peptide that activates melanocortin receptors. Its pharmacological activity involves receptor-mediated cellular signaling rather than direct hormonal replacement or androgen receptor stimulation.

Step 1 – Introduction Into the Biological System

PT-141 enters the biological environment according to its formulation and route of administration. Pharmaceutical bremelanotide is administered subcutaneously, but the administration characteristics of the Biochem 12.5 mg product have not been confirmed.

Step 2 – Interaction With Melanocortin Receptors

Bremelanotide binds to melanocortin receptors, including MC1R, MC3R, MC4R, and MC5R. These receptors belong to the G protein-coupled receptor family and participate in several physiological signaling pathways.

Step 3 – Activation of Intracellular Signaling

Melanocortin receptor activation can stimulate intracellular signaling involving cyclic adenosine monophosphate (cAMP). These signaling mechanisms contribute to cellular responses associated with receptor activation.

Step 4 – Influence on Central Sexual Response Pathways

Through melanocortin receptor signaling, PT-141 influences central pathways associated with sexual desire and motivation. The precise relationship between receptor activation and clinical improvement in sexual desire is not fully understood.

Step 5 – Peptide Metabolism and Elimination

Bremelanotide undergoes biological distribution, peptide metabolism, and elimination. Its pharmacokinetic characteristics depend on the formulation, route of administration, and physiological conditions.

The reported terminal elimination half-life of pharmaceutical bremelanotide is approximately 2.7 hours following subcutaneous administration. This value describes a studied pharmaceutical preparation and should not automatically be applied to an unverified formulation.

PT-141 formulations differ from anabolic steroid oil solutions and conventional small-molecule preparations because PT-141 is a synthetic cyclic peptide with distinct receptor activity and chemical stability characteristics.

Their formulation characteristics may include:

• Bremelanotide (PT-141) as the labeled active ingredient.
• A labeled quantity of 12.5 mg per vial.
• A cyclic heptapeptide molecular structure.
• Melanocortin receptor agonist activity.
• Lyophilized or liquid presentations, depending on the formulation.
• Excipients selected to support peptide stability.
• Formulation-dependent sensitivity to temperature, pH, and degradation.
• Packaging and storage requirements determined by the product composition.

The precise formulation, salt form, and excipient composition of Biochem PT-141 12.5 mg have not been confirmed.

Formulation ingredients do not independently produce the melanocortin receptor activity associated with bremelanotide.

United States

Biochem PT-141 12.5mg, Biochem PT141 12.5mg USA, Bremelanotide 12.5mg United States, PT-141 peptide 12.5mg, PT141 12.5mg vial, bremelanotide peptide, PT-141 properties, PT-141 description, PT-141 how it works, PT-141 composition, PT-141 pharmacology, PT-141 melanocortin receptors, PT-141 MC4R signaling, PT-141 sexual desire pathways, PT-141 central nervous system, PT-141 neuropeptide activity, bremelanotide mechanism of action, PT-141 peptide structure, melanocortin receptor agonist.

Canada

English: Biochem PT-141 12.5mg Canada, Bremelanotide 12.5mg Canada, PT141 peptide 12.5mg Canada, PT-141 12.5mg vial, PT-141 properties, PT-141 formulation, PT-141 melanocortin signaling, PT-141 MC4R receptor, bremelanotide sexual desire pathways, PT-141 peptide composition.

French: Biochem PT-141 12,5 mg Canada, brémélanotide 12,5 mg, peptide PT-141 12,5 mg, flacon PT-141 12,5 mg, propriétés du PT-141, composition du PT-141, récepteurs mélanocortines, signalisation MC4R, désir sexuel, neuropeptide, mécanisme d'action du brémélanotide.

United Kingdom

Biochem PT-141 12.5mg UK, Bremelanotide 12.5mg UK, PT141 peptide 12.5mg UK, PT-141 12.5mg vial UK, PT-141 properties, PT-141 pharmacology, melanocortin receptor agonist, PT-141 MC4R signaling, bremelanotide sexual desire pathways, PT-141 peptide composition, PT-141 mechanism of action.

Germany

Biochem PT-141 12,5 mg Deutschland, Bremelanotid 12,5 mg, PT-141 Peptid 12,5 mg, PT-141 12,5 mg Fläschchen, PT-141 Eigenschaften, PT-141 Wirkungsmechanismus, PT-141 Zusammensetzung, Melanocortin-Rezeptor-Agonist, MC4R-Signalweg, sexuelles Verlangen, zentrale Nervensystem-Signalwege, Bremelanotid Peptidstruktur.

France

Biochem PT-141 12,5 mg France, brémélanotide 12,5 mg, peptide PT-141 12,5 mg, flacon PT-141 12,5 mg, propriétés du PT-141, mécanisme d'action du brémélanotide, composition du PT-141, agoniste des récepteurs mélanocortines, signalisation MC4R, désir sexuel, système nerveux central, structure du peptide PT-141.

Spain

Biochem PT-141 12,5 mg España, bremelanotida 12,5 mg, péptido PT-141 12,5 mg, vial PT-141 12,5 mg, propiedades del PT-141, cómo funciona la bremelanotida, composición del PT-141, agonista de receptores de melanocortina, señalización MC4R, deseo sexual, sistema nervioso central, mecanismo de acción del PT-141.

Italy

Biochem PT-141 12,5 mg Italia, bremelanotide 12,5 mg, peptide PT-141 12,5 mg, flaconcino PT-141 12,5 mg, proprietà del PT-141, meccanismo d'azione bremelanotide, composizione del PT-141, agonista dei recettori della melanocortina, segnalazione MC4R, desiderio sessuale, sistema nervoso centrale, struttura del peptide PT-141.

Portugal

Biochem PT-141 12,5 mg Portugal, bremelanotida 12,5 mg, peptídeo PT-141 12,5 mg, frasco PT-141 12,5 mg, propriedades do PT-141, mecanismo de ação bremelanotida, composição do PT-141, agonista dos recetores de melanocortina, sinalização MC4R, desejo sexual, sistema nervoso central, estrutura do peptídeo PT-141.

Netherlands

Biochem PT-141 12,5 mg Nederland, bremelanotide 12,5 mg, PT-141 peptide 12,5 mg, PT-141 12,5 mg flacon, eigenschappen van PT-141, werkingsmechanisme bremelanotide, samenstelling van PT-141, melanocortinereceptoragonist, MC4R-signalering, seksueel verlangen, centraal zenuwstelsel, PT-141 peptidestructuur.

Belgium

Biochem PT-141 12,5 mg Belgium, PT-141 12,5 mg België, PT-141 12,5 mg Belgique, bremelanotide, brémélanotide, eigenschappen van PT-141, propriétés du PT-141, melanocortinereceptoren, récepteurs mélanocortines, MC4R-signalering, signalisation MC4R, seksueel verlangen, désir sexuel, centraal zenuwstelsel, système nerveux central.

Switzerland

Biochem PT-141 12,5 mg Switzerland, PT-141 12,5 mg Schweiz, PT-141 12,5 mg Suisse, Bremelanotid, brémélanotide, PT-141 Eigenschaften, propriétés du PT-141, Melanocortin-Rezeptoren, récepteurs mélanocortines, MC4R-Signalweg, signalisation MC4R, sexuelles Verlangen, désir sexuel, zentrales Nervensystem.

Austria

Biochem PT-141 12,5 mg Österreich, Bremelanotid 12,5 mg, PT-141 Peptid 12,5 mg, PT-141 12,5 mg Fläschchen, PT-141 Eigenschaften, PT-141 Wirkungsmechanismus, Melanocortin-Rezeptor-Agonist, MC4R-Signalweg, sexuelles Verlangen, zentrales Nervensystem, PT-141 Zusammensetzung.

Sweden

Biochem PT-141 12,5 mg Sverige, bremelanotid 12,5 mg, PT-141 peptid 12,5 mg, PT-141 12,5 mg injektionsflaska, PT-141 egenskaper, PT-141 verkningsmekanism, melanokortinreceptoragonist, MC4R-signalering, sexuell lust, centrala nervsystemet, PT-141 peptidstruktur.

Norway

Biochem PT-141 12,5 mg Norge, bremelanotid 12,5 mg, PT-141 peptid 12,5 mg, PT-141 12,5 mg hetteglass, PT-141 egenskaper, PT-141 virkningsmekanisme, melanokortinreseptoragonist, MC4R-signalering, seksuell lyst, sentralnervesystemet, PT-141 peptidstruktur.

Denmark

Biochem PT-141 12,5 mg Danmark, bremelanotid 12,5 mg, PT-141 peptid 12,5 mg, PT-141 12,5 mg hætteglas, PT-141 egenskaber, PT-141 virkningsmekanisme, melanocortinreceptoragonist, MC4R-signalering, seksuel lyst, centralnervesystemet, PT-141 peptidstruktur.

Finland

Biochem PT-141 12,5 mg Suomi, bremelanotidi 12,5 mg, PT-141 peptidi 12,5 mg, PT-141 12,5 mg injektiopullo, PT-141 ominaisuudet, PT-141 vaikutusmekanismi, melanokortiinireseptorin agonisti, MC4R-signalointi, seksuaalinen halu, keskushermosto, PT-141 peptidirakenne.

Poland

Biochem PT-141 12,5 mg Polska, bremelanotyd 12,5 mg, peptyd PT-141 12,5 mg, fiolka PT-141 12,5 mg, właściwości PT-141, mechanizm działania bremelanotydu, skład PT-141, agonista receptorów melanokortynowych, sygnalizacja MC4R, pożądanie seksualne, ośrodkowy układ nerwowy, struktura peptydu PT-141.

Czech Republic

Biochem PT-141 12,5 mg Česko, bremelanotid 12,5 mg, peptid PT-141 12,5 mg, lahvička PT-141 12,5 mg, vlastnosti PT-141, mechanismus účinku bremelanotidu, složení PT-141, agonista melanokortinových receptorů, signalizace MC4R, sexuální touha, centrální nervový systém, struktura peptidu PT-141.

Romania

Biochem PT-141 12,5 mg România, bremelanotidă 12,5 mg, peptidă PT-141 12,5 mg, flacon PT-141 12,5 mg, proprietăți PT-141, mecanism de acțiune bremelanotidă, compoziția PT-141, agonist al receptorilor melanocortinei, semnalizare MC4R, dorință sexuală, sistem nervos central, structura peptidei PT-141.

Greece

Biochem PT-141 12,5 mg Ελλάδα, βρεμελανοτίδη 12,5 mg, πεπτίδιο PT-141 12,5 mg, φιαλίδιο PT-141 12,5 mg, ιδιότητες PT-141, μηχανισμός δράσης βρεμελανοτίδης, σύνθεση PT-141, αγωνιστής υποδοχέων μελανοκορτίνης, σηματοδότηση MC4R, σεξουαλική επιθυμία, κεντρικό νευρικό σύστημα, δομή πεπτιδίου PT-141.

Ireland

Biochem PT-141 12.5mg Ireland, Bremelanotide 12.5mg Ireland, PT141 peptide 12.5mg Ireland, PT-141 12.5mg vial Ireland, PT-141 properties, PT-141 pharmacology, melanocortin receptor agonist, PT-141 MC4R signaling, bremelanotide sexual desire pathways, PT-141 peptide composition, PT-141 mechanism of action.

Colombia

Biochem PT-141 12,5 mg Colombia, bremelanotida 12,5 mg Colombia, péptido PT-141 12,5 mg, vial PT-141 12,5 mg, propiedades del PT-141, cómo funciona la bremelanotida, farmacología del PT-141, composición del PT-141, receptores de melanocortina, señalización MC4R, deseo sexual, sistema nervioso central, mecanismo de acción del PT-141, descripción de la bremelanotida.

Argentina

Biochem PT-141 12,5 mg Argentina, bremelanotida 12,5 mg Argentina, péptido PT-141 12,5 mg, vial PT-141 12,5 mg, propiedades del PT-141, qué es la bremelanotida, cómo actúa el PT-141, farmacología del PT-141, receptores de melanocortina, señalización MC4R, deseo sexual, sistema nervioso central, composición del PT-141.

México

Biochem PT-141 12,5 mg México, bremelanotida 12,5 mg México, péptido PT-141 12,5 mg, vial PT-141 12,5 mg, propiedades del PT-141, para qué se utiliza la bremelanotida, cómo funciona el PT-141, farmacología del PT-141, receptores de melanocortina, señalización MC4R, deseo sexual, sistema nervioso central, mecanismo de acción del PT-141.

Perú

Biochem PT-141 12,5 mg Perú, bremelanotida 12,5 mg Perú, péptido PT-141 12,5 mg, vial PT-141 12,5 mg, propiedades del PT-141, qué es la bremelanotida, cómo funciona el PT-141, farmacología del PT-141, receptores de melanocortina, señalización MC4R, deseo sexual, sistema nervioso central, composición del PT-141.

Venezuela

Biochem PT-141 12,5 mg Venezuela, bremelanotida 12,5 mg Venezuela, péptido PT-141 12,5 mg, vial PT-141 12,5 mg, propiedades del PT-141, qué es la bremelanotida, cómo actúa el PT-141, farmacología del PT-141, receptores de melanocortina, señalización MC4R, deseo sexual, sistema nervioso central, composición del PT-141.

Ecuador

Biochem PT-141 12,5 mg Ecuador, bremelanotida 12,5 mg Ecuador, péptido PT-141 12,5 mg, vial PT-141 12,5 mg, propiedades del PT-141, para qué se estudia la bremelanotida, cómo funciona el PT-141, farmacología del PT-141, receptores de melanocortina, señalización MC4R, deseo sexual, sistema nervioso central, composición del PT-141, mecanismo de acción del PT-141, descripción de la bremelanotida.

Biochem PT-141 12.5mg | Bremelanotide Peptide

Learn about Biochem PT-141 12.5mg, also known as Bremelanotide, a melanocortin receptor agonist associated with central nervous system signaling and sexual desire pathways.

Biochem PT-141 12,5mg | Péptido Bremelanotida

Conoce Biochem PT-141 12,5mg, también conocido como bremelanotida, un péptido agonista de receptores de melanocortina relacionado con la señalización del sistema nervioso central y las vías del deseo sexual.

biochem-pt-141-12-5mg-bremelanotide-peptide

biochem-pt-141-12-5mg-peptido-bremelanotida

Biochem PT-141 12.5mg peptide vial labeled as containing Bremelanotide, a synthetic cyclic heptapeptide associated with melanocortin receptor activation, MC4R signaling, and central sexual desire pathways.

Biochem PT-141 12,5mg vial de péptido etiquetado como bremelanotida, un heptapéptido cíclico sintético relacionado con la activación de receptores de melanocortina, la señalización MC4R y las vías centrales del deseo sexual.